293 related articles for article (PubMed ID: 15523003)
1. Mechanism-based inactivation of CYP3A by HIV protease inhibitors.
Ernest CS; Hall SD; Jones DR
J Pharmacol Exp Ther; 2005 Feb; 312(2):583-91. PubMed ID: 15523003
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Granfors MT; Wang JS; Kajosaari LI; Laitila J; Neuvonen PJ; Backman JT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):79-85. PubMed ID: 16433896
[TBL] [Abstract][Full Text] [Related]
3. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction.
Kumar GN; Dykstra J; Roberts EM; Jayanti VK; Hickman D; Uchic J; Yao Y; Surber B; Thomas S; Granneman GR
Drug Metab Dispos; 1999 Aug; 27(8):902-8. PubMed ID: 10421617
[TBL] [Abstract][Full Text] [Related]
4. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
[TBL] [Abstract][Full Text] [Related]
5. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors.
Huang L; Wring SA; Woolley JL; Brouwer KR; Serabjit-Singh C; Polli JW
Drug Metab Dispos; 2001 May; 29(5):754-60. PubMed ID: 11302944
[TBL] [Abstract][Full Text] [Related]
6. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
Ma B; Prueksaritanont T; Lin JH
Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo effects of the arylamine human immunodeficiency virus protease inhibitor 4R-(4alpha,5alpha,6beta, 7beta)-1-[(3-(1-imidazoylcarbamoyl)phenyl)methyl]-3-[(3-aminophenyl)m ethyl]hexahydro-5,6-dihydroxy-4,7-bis(phenylmethyl)-2H-1, 3-diazepin-2-one (SD894) on rat hepatic cytochrome P450 2B and 3A.
Grubb MF; Diamond S; Christ DD
Drug Metab Dispos; 1997 Dec; 25(12):1424-8. PubMed ID: 9394033
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors.
Iribarne C; Berthou F; Carlhant D; Dreano Y; Picart D; Lohezic F; Riche C
Drug Metab Dispos; 1998 Mar; 26(3):257-60. PubMed ID: 9492389
[TBL] [Abstract][Full Text] [Related]
9. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome P450 3A.
Voorman RL; Maio SM; Payne NA; Zhao Z; Koeplinger KA; Wang X
J Pharmacol Exp Ther; 1998 Oct; 287(1):381-8. PubMed ID: 9765359
[TBL] [Abstract][Full Text] [Related]
10. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir.
Weemhoff JL; von Moltke LL; Richert C; Hesse LM; Harmatz JS; Greenblatt DJ
J Pharm Pharmacol; 2003 Mar; 55(3):381-6. PubMed ID: 12724045
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 3A-mediated metabolism of buspirone in human liver microsomes.
Zhu M; Zhao W; Jimenez H; Zhang D; Yeola S; Dai R; Vachharajani N; Mitroka J
Drug Metab Dispos; 2005 Apr; 33(4):500-7. PubMed ID: 15640381
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: major role of CYP3A.
Desta Z; Soukhova N; Morocho AM; Flockhart DA
J Pharmacol Exp Ther; 2001 Aug; 298(2):508-20. PubMed ID: 11454912
[TBL] [Abstract][Full Text] [Related]
13. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
[TBL] [Abstract][Full Text] [Related]
14. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
15. Alprazolam-ritonavir interaction: implications for product labeling.
Greenblatt DJ; von Moltke LL; Harmatz JS; Durol AL; Daily JP; Graf JA; Mertzanis P; Hoffman JL; Shader RI
Clin Pharmacol Ther; 2000 Apr; 67(4):335-41. PubMed ID: 10801241
[TBL] [Abstract][Full Text] [Related]
16. Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.
Zhao XJ; Jones DR; Wang YH; Grimm SW; Hall SD
Xenobiotica; 2002 Oct; 32(10):863-78. PubMed ID: 12419016
[TBL] [Abstract][Full Text] [Related]
17. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions.
Decker CJ; Laitinen LM; Bridson GW; Raybuck SA; Tung RD; Chaturvedi PR
J Pharm Sci; 1998 Jul; 87(7):803-7. PubMed ID: 9649346
[TBL] [Abstract][Full Text] [Related]
18. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
19. Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.
Mori K; Hashimoto H; Takatsu H; Tsuda-Tsukimoto M; Kume T
Xenobiotica; 2009 Jun; 39(6):415-22. PubMed ID: 19480547
[TBL] [Abstract][Full Text] [Related]
20. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Zalma A; von Moltke LL; Granda BW; Harmatz JS; Shader RI; Greenblatt DJ
Biol Psychiatry; 2000 Apr; 47(7):655-61. PubMed ID: 10745059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
